Pasithea Therapeutics Corp. (KTTA) EV/EBITDA Multiple
Pasithea Therapeutics (KTTA) develops drugs to combat severe inflammation and brain lesions, leveraging long-term patent protection. The price indicator on the chart confirms the effectiveness of this strategy, reaching a value of 0.00. Management is focusing on innovative treatment of depression via the immune system, while a streamlined raw material supply chain ensures the uninterrupted execution of all clinical trials for CNS drugs.
KTTA (pasitheaclinics.com): analytical breakdowns and indicator data
- market price and analyst price targets:
- market capitalization details:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Pasithea Therapeutics|KTTA - Long-Term Liabilities to Capital|Short-Term Debt to Capital Pasithea Therapeutics Corp.|KTTA - Company Aggregate Debts|Debt to Book Value Pasithea Therapeutics Corp.|KTTA - Company Long-Term Loans and Borrowings|Company Current Liabilities Pasithea Therapeutics|Quick Ratio pasitheaclinics.com
- net income and valuation multiples indicators:
KTTA - Final Profit|Projected Future Earnings Pasithea Therapeutics|KTTA - Market Cap to Earnings|Future Price to Earnings Pasithea Therapeutics Corp.|KTTA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Pasithea Therapeutics Corp.|KTTA - Operating profit EBITDA|Earnings per share for the last twelve months Pasithea Therapeutics|KTTA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth pasitheaclinics.com|KTTA - Earnings per share growth rate in current year|Expected earnings per share growth for next year Pasithea Therapeutics
Fundamental company analysis:Pasithea (KTTA)
For Pasithea Therapeutics (KTTA), which relies on a stable pool of neurobiologists, EV/EBITDA serves as a tool for assessing business value while accounting for all debt obligations. The EV/EBITDA trajectory of Pasithea Therapeutics reflects the ratio of total enterprise value to operating income before taxes and amortization, eliminating the impact of financing structure. Investors should interpret the dynamics of this metric as a measure of how effectively the company capitalizes its intellectual potential into real profit.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Biogen Corp BIIB|Total Company Value to Operating Income Before Depreciation Ratio Neurocrine Corp (NBIX)|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|XENE: Enterprise Value to Operating Income Before Depreciation Ratio|VKTX (Viking Pharma) - EV/EBITDA Multiple|SUPN: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CPRX|DNLI - Company Value to EBITDA|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|EV/EBITDA Multiple Biohaven Ltd BHVN|AMLX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX (Praxis Precision Medicines) - Enterprise Value to EBITDA Ratio|AVXL: Enterprise Value to Operating Income Before Depreciation Ratio|CBLL (CeriBell) - EV/EBITDA Multiple|PRTA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ALEC|ANNX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omeros OMER|Business Value to Operating Income Before Depreciation NGNE|AC Immune SA - EV/EBITDA Multiple|VYGR - EV/EBITDA Multiple|Neumora Therapeutics Inc (NMRA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio SCLX (Scilex Holding Company, Inc.)|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Company Value to EBITDA Alpha Cognition Corp ACOG|Enterprise Value to EBITDA Ratio CGTX (Cognition Therapeutics, Inc.)|EV/EBITDA Multiple Inhibikase Therapeutics Inc (IKT)|Cassava - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio ASRT (Assertio Holdings)|Coya - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Vistagen Therapeutics VTGN|OVID: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Acumen Pharmaceuticals Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Alterity Therapeutics Ltd (ATHE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Clene Inc. (CLNN)|EV/EBITDA Multiple pepgen.com (PEPG)|Jupiter Neurosciences - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio RLMD (Relmada Therapeutics Inc)|ANVS: Enterprise Value to EBITDA Ratio|Grace Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|AIFF: EV/EBITDA Multiple|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|Enterprise Value to Operating Income Before Depreciation RVPH (Reviva Pharmaceuticals Holdings Inc.)|EV/EBITDA Multiple MTVA|NRXS - Company Value to EBITDA|Helius Medical Technologies - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Passage Bio Inc. PASG|NEUP - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation NERV (Minerva Neurosciences Inc)|Athira (ATHA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Addex (ADXN)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alzamend Neuro Inc.|Cyclerion - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTIX|EV/EBITDA Multiple cortigent.com (CRGT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avenue Therapeutics, Inc ATXI|Total Company Value to Operating Income Before Depreciation Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio chromocell.com CHRO|ELYM (eliemtx.com) - Enterprise Value to EBITDA Ratio|ITCI: Enterprise Value to Operating Income Before Depreciation Ratio|LBPH (Longboard Pharma) - EV/EBITDA Multiple|MRNS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|EV/EBITDA Multiple SAGE (Sage Therapeutics)|EV/EBITDA Multiple Synaptogenix Inc. SNPX|TRVN: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VIGL (Vigil Neuroscience)|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|CERE: Enterprise Value to Operating Income Before Depreciation Ratio
